Literature DB >> 25039269

Clinical predictors of recurrent Clostridium difficile infection in out-patients.

R Shivashankar1, S Khanna, P P Kammer, W Scott Harmsen, A R Zinsmeister, L M Baddour, D S Pardi.   

Abstract

BACKGROUND: Clostridium difficile infection (CDI) recurs in 20-30% of patients. AIM: To describe the predictors of recurrence in out-patients with CDI.
METHODS: Out-patient cases of CDI in Olmsted County, MN residents diagnosed between 28 June 2007 and 25 June 2010 were identified. Recurrent CDI was defined as recurrence of diarrhoea with a positive C. difficile PCR test from 15 to 56 days after the initial diagnosis with interim resolution of symptoms. Patients who had two positive tests within 14 days were excluded. Cox proportional hazard models were used to assess the association of clinical variables with time to recurrence of CDI.
RESULTS: The cohort included 520 out-patients; 104 had recurrent CDI (cumulative incidence of 17.5% by 30 days). Univariate analysis identified increasing age and antibiotic use to be associated with recurrent CDI. Severe CDI, peripheral leucocyte count and change in serum creatinine >1.5-fold were not. In a multiple variable model, concomitant antibiotic use was associated with risk of recurrent CDI (HR = 5.4, 95% CI 1.6-17.5, P = 0.005), while age (HR per 10 year increase = 1.1, 95% CI 0.9-1.3, P = 0.22); peripheral leucocyte count >15 × 10(9) /L (HR = 1.0, 95% CI 0.5-2.1, P = 0.92); and change in serum creatinine greater than 1.5-fold (HR = 0.8, 95% CI 0.4-1.5, P = 0.44) were not.
CONCLUSIONS: Antibiotic use was independently associated with a dramatic risk of recurrent Clostridium difficile infection in an out-patient cohort. It is important to avoid unnecessary systemic antibiotics in patients with Clostridium difficile infection, and patients with ongoing antibiotic use should be monitored closely for recurrent infection.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25039269      PMCID: PMC4135383          DOI: 10.1111/apt.12864

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  22 in total

Review 1.  Meeting the challenge of recurrent Clostridium difficile infection.

Authors:  Stuart Johnson
Journal:  J Hosp Med       Date:  2012-03       Impact factor: 2.960

Review 2.  Recurrent clostridium difficile.

Authors:  Seema Maroo; J Thomas Lamont
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

3.  Risk factors for severity and relapse of pseudomembranous colitis in an elderly population.

Authors:  M Moshkowitz; E Ben-Baruch; Z Kline; Z Shimoni; M Niven; F Konikoff
Journal:  Colorectal Dis       Date:  2007-02       Impact factor: 3.788

Review 4.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

Review 5.  Clostridium difficile infection: new insights into management.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Mayo Clin Proc       Date:  2012-11       Impact factor: 7.616

6.  Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study.

Authors:  Sahil Khanna; Scott L Aronson; Patricia P Kammer; Larry M Baddour; Darrell S Pardi
Journal:  Mayo Clin Proc       Date:  2012-07       Impact factor: 7.616

7.  Rifaximin in the treatment of recurrent Clostridium difficile infection.

Authors:  E Mattila; P Arkkila; P S Mattila; E Tarkka; P Tissari; V-J Anttila
Journal:  Aliment Pharmacol Ther       Date:  2012-10-24       Impact factor: 8.171

8.  Meta-analysis to assess risk factors for recurrent Clostridium difficile infection.

Authors:  K W Garey; S Sethi; Y Yadav; H L DuPont
Journal:  J Hosp Infect       Date:  2008-10-31       Impact factor: 3.926

9.  Diverticular disease of the colon does not increase risk of repeat C. difficile infection.

Authors:  Paul Feuerstadt; Rohit Das; Lawrence J Brandt
Journal:  J Clin Gastroenterol       Date:  2013 May-Jun       Impact factor: 3.062

10.  An evaluation of repeat stool testing for Clostridium difficile infection by polymerase chain reaction.

Authors:  Sahil Khanna; Darrell S Pardi; Jon E Rosenblatt; Robin Patel; Patricia P Kammer; Larry M Baddour
Journal:  J Clin Gastroenterol       Date:  2012 Nov-Dec       Impact factor: 3.062

View more
  15 in total

1.  Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection.

Authors:  Sahil Khanna; Arjun Gupta; Larry M Baddour; Darrell S Pardi
Journal:  Intern Emerg Med       Date:  2015-12-22       Impact factor: 3.397

2.  Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection.

Authors:  Sahil Khanna; Emmanuel Montassier; Bradley Schmidt; Robin Patel; Daniel Knights; Darrell S Pardi; Purna Kashyap
Journal:  Aliment Pharmacol Ther       Date:  2016-08-02       Impact factor: 8.171

Review 3.  Recent Issues in Pediatric Clostridium difficile Infection.

Authors:  Jason A Clayton; Philip Toltzis
Journal:  Curr Infect Dis Rep       Date:  2017-11-07       Impact factor: 3.725

4.  Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles.

Authors:  J R Allegretti; S Kearney; N Li; E Bogart; K Bullock; G K Gerber; L Bry; C B Clish; E Alm; J R Korzenik
Journal:  Aliment Pharmacol Ther       Date:  2016-04-18       Impact factor: 8.171

5.  Derivation and Validation of a Clostridium difficile Infection Recurrence Prediction Rule in a National Cohort of Veterans.

Authors:  Kelly R Reveles; Eric M Mortensen; Jim M Koeller; Kenneth A Lawson; Mary Jo V Pugh; Sarah A Rumbellow; Jacqueline R Argamany; Christopher R Frei
Journal:  Pharmacotherapy       Date:  2018-02-22       Impact factor: 4.705

6.  High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection.

Authors:  A Wadhwa; M F Al Nahhas; R A Dierkhising; R Patel; P Kashyap; D S Pardi; S Khanna; M Grover
Journal:  Aliment Pharmacol Ther       Date:  2016-07-22       Impact factor: 8.171

Review 7.  The Microbiome and Sustainable Healthcare.

Authors:  Rodney R Dietert; Janice M Dietert
Journal:  Healthcare (Basel)       Date:  2015-03-03

8.  Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.

Authors:  Vimalanand S Prabhu; Oliver A Cornely; Yoav Golan; Erik R Dubberke; Sebastian M Heimann; Mary E Hanson; Jane Liao; Alison Pedley; Mary Beth Dorr; Stephen Marcella
Journal:  Clin Infect Dis       Date:  2017-10-01       Impact factor: 9.079

9.  Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials.

Authors:  Yoav Golan; Herbert L DuPont; Fernando Aldomiro; Erin H Jensen; Mary E Hanson; Mary Beth Dorr
Journal:  Open Forum Infect Dis       Date:  2020-06-26       Impact factor: 3.835

10.  Use of Concomitant Antibiotics During Treatment for Clostridium difficile Infection (CDI) in Pediatric Inpatients: An Observational Cohort Study.

Authors:  Vanessa W Stevens; Cary Thurm; Elyse M Schwab; Matthew P Kronman; Jeffrey S Gerber; Samir S Shah; Jason G Newland; Joshua Courter; Sarah Parker; Thomas V Brogan; Adam L Hersh
Journal:  Infect Dis Ther       Date:  2016-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.